Expertise in
10
conditions

Dr. Marco Davila

Oncology
Urology Of Virginia PLLC
12902 Usf Magnolia Dr, 
Tampa, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
10
conditions
Urology Of Virginia PLLC
12902 Usf Magnolia Dr, 
Tampa, FL 

Overview

Marco Davila is an Oncologist practicing medicine in Tampa, Florida.

Dr. Davila is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, B-Cell Lymphoma, Smoldering Multiple Myeloma, Mantle Cell Lymphoma (MCL), and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 113 peer reviewed articles and participating in 9 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in TN

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

Urology of Virginia PLLC
12902 Usf Magnolia Dr, Tampa, FL 33612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase I Clinical Trial of an Infusion of Autologous T Cells Genetically Engineered With a Chimeric Receptor to Target the Follicle-Stimulating Hormone Receptor in Patients With Recurrent Ovarian Cancer
A Phase I Clinical Trial of an Infusion of Autologous T Cells Genetically Engineered With a Chimeric Receptor to Target the Follicle-Stimulating Hormone Receptor in Patients With Recurrent Ovarian Cancer
Enrollment Status: Recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Phase: Phase 1
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
Enrollment Status: Completed
Publish Date: April 02, 2026
Intervention Type: Drug
Study Drugs: BMS-986004, Sirolimus, Tacrolimus
Study Phase: Phase 1
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Enrollment Status: Completed
Publish Date: April 02, 2026
Intervention Type: Drug, Procedure
Study Drugs: Pacritinib, Sirolimus, Tacrolimus
Study Phase: Phase 1/Phase 2
CD8 Depleted, Non-Engrafting, HLA Mismatched Unrelated Donor Lymphocyte Infusion in Patients With MDA and Secondary AML
CD8 Depleted, Non-Engrafting, HLA Mismatched Unrelated Donor Lymphocyte Infusion in Patients With MDA and Secondary AML
Enrollment Status: Completed
Publish Date: February 19, 2026
Intervention Type: Drug, Biological
Study Drug: CD8-Depleted Donor Lymphocyte Infusion
Study Phase: Phase 1/Phase 2
Phase 1/1b Trial of Donor γδ T--Cell Infusion for Treatment of Patients With Acute Myeloid Leukemia at High Risk of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Phase 1/1b Trial of Donor γδ T--Cell Infusion for Treatment of Patients With Acute Myeloid Leukemia at High Risk of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Active_not_recruiting
Publish Date: February 09, 2026
Intervention Type: Biological
Study Drug: Gamma Delta T-Cell Infusion
Study Phase: Phase 1
Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination With Pneumococcal 13-valent Conjugate Vaccine Before and After CD19-targeted CAR T-cell Immunotherapy
Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination With Pneumococcal 13-valent Conjugate Vaccine Before and After CD19-targeted CAR T-cell Immunotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Biological
Study Drugs: Pneumococcal conjugate vaccine (PCV13), CD19 targeted CAR T Cell Therapy
Study Phase: Phase 2
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: December 11, 2025
Intervention Type: Radiation, Drug
Study Drugs: Fludarabine, Melphalan
Study Phase: Phase 2
A Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haploidentical Peripheral Blood Stem Cell Transplantation
A Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haploidentical Peripheral Blood Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug, Procedure, Radiation
Study Phase: Phase 1
A Phase II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat for Graft Versus Host Disease (GVHD) Prevention
A Phase II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat for Graft Versus Host Disease (GVHD) Prevention
Enrollment Status: Completed
Publish Date: July 21, 2021
Intervention Type: Drug
Study Drugs: Panobinostat, Sirolimus, Tacrolimus
Study Phase: Phase 2
View 8 Less Clinical Trials

113 Total Publications

A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphoma.
A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphoma.
Journal: medRxiv : the preprint server for health sciences
Published: April 10, 2026
Similar Doctors
Expertise in
46
conditions
Expertise in
46
conditions
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (1045.5 miles away)
813-934-6811
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Philippe Spiess is an Oncologist practicing medicine in Tampa, Florida. Dr. Spiess is highly rated in 46 conditions, according to our data. His clinical expertise encompasses Penile Cancer, Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Cystectomy. Dr. Spiess is currently accepting new patients.

Expertise in
45
conditions
Expertise in
45
conditions
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (1045.5 miles away)
888-663-3488
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Julio Chavez is an Oncologist practicing medicine in Tampa, Florida. Dr. Chavez is highly rated in 45 conditions, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Non-Hodgkin Lymphoma, Follicular Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
41
conditions
Dr. Andrew Kuykendall
Hematology | Oncology
Expertise in
41
conditions
Dr. Andrew Kuykendall
Hematology | Oncology
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (1045.5 miles away)
813-701-3769
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Kuykendall is a Hematologist and an Oncologist practicing medicine in Tampa, Florida. Dr. Kuykendall is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Polycythemia Vera, Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasms (MPN), and Bone Marrow Aspiration. Dr. Kuykendall is currently accepting new patients.

Frequently Asked Questions about Dr. Marco Davila

How do I make an appointment with Dr. Marco Davila?

You can book an appointment with Dr. Marco Davila by calling their office at 888-663-3488. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Marco Davila a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Marco Davila is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Marco Davila specialize in?

While Dr. Marco Davila is a Oncology, they have specific expertise in Multiple Myeloma, B-Cell Lymphoma, and Smoldering Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Marco Davila participate in research or clinical trials?

Yes. Dr. Marco Davila has published 113 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Marco Davila's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Marco Davila accept my insurance?

Dr. Marco Davila accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 888-663-3488 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Davila's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile